(Companies Covered: AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG,null, NewLink Genetics Corporation, Seattle Genetics, Celldex Therapeutics, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co., Ltd, Juno Therapeutics, Kite Pharma)
The global checkpoint inhibitors market is expected to decline from $15.44 billion in 2019 to $15.20 billion in 2020 at a compound annual growth rate of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $29.77 billion in 2023 at a rate of 25.11%.
Read More On The Global Checkpoint Inhibitors Market Report At –
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitors-global-market-report-2020-30-covid-19-growth-and-change
The checkpoint inhibitors market consists of sales of the immune checkpoint inhibitor drugs and related services by entities (organizations, sole traders and partnerships) that produce checkpoint inhibitors for treating cancer. A checkpoint inhibitor is a drug that blocks proteins that stop the body’s immune system from killing the cancer cells. One type of cell in the immune system that fights the cancer cells are T-cells.
Global Checkpoint Inhibitors Market Segmentation –
1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others.
2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Others.
Global Checkpoint Inhibitors Market Driver –
The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.
Request For A Sample Of The Global Checkpoint Inhibitors Market Report At –
https://www.thebusinessresearchcompany.com/sample.aspx?id=3413&type=smp
Few Points From The Global Checkpoint Inhibitors Market TOC
1. Executive Summary
2. Checkpoint Inhibitors Market Characteristics
3. Checkpoint Inhibitors Market Size And Growth
3.1. Global Checkpoint Inhibitors Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Checkpoint Inhibitors Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Checkpoint Inhibitors Market Segmentation
4.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2015-2019,
2023F, 2025F, 2030F, $ Billion
4.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2015
2019, 2023F, 2025F, 2030F, $ Billion
5. Checkpoint Inhibitors Market Regional And Country Analysis
5.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2015-2019, 2023F,
2025F, 2030F, $ Billion
5.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2015-2019, 2023F,
2025F, 2030F, $ Billion
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
Address:
City: London
State: Greater London
Country: United Kingdom
Website: https://www.thebusinessresearchcompany.com/